Anadis in Merck Phase IV study
Thursday, 23 October, 2008
An antibody developed by Melbourne company Anadis (ASX: ANX) will be used in combination with a new integrase inhibitor developed by Merck in a multi-site Phase IV trial in HIV patients.
The Anadis product, a high affinity anti-lipopolysaccharide (LPS) antibody called BioGard, is aimed at enhancing immune function and reducing local immune activation, particularly in the gastrointestinal system.
The trial will investigate its ability as an adjunctive therapy with Isentress (raltegravir), the first integrase inhibitor to receive FDA approval.
The multi-site, randomised double-blind placebo controlled study, named CORAL, is being sponsored by the Australian National Centre in HIV Epidemiology and Clinical Research (NCHECR).
The aim is to see if BioGard, supplementing Isentress, can reduce gastrointestinal immune activation and allow rebuilding of immune competence in HIV patients with continuing HIV viral replication.
Results are expected next year.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
